Nd We Have Continued To Gather Pace Since Reimbursement Came Into Effect On 1 July Quickly Builta Diversified Customer Base And Continue Add New Sites Notably News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise stated.[1] All figures are provided on an unaudited basis. Financial Summary Telix reports total revenue of $55.3 million from global sales of Illuccix, up 168% on the previous quarter ($20.6 million, Q2 2022) U.S. sales of Illuccix up 178% to $53.7 million (US$36.4 million) in second quarter of commercial sales ($19.3 million, Q2 2022) Cash balance of $117.1 million; provides 21 quarters of cash runway (based on Q3 2022 burn rate) Net operating cash outflow reduced by $20.5 million to $5.3 million, a significant reduction on the prior quarter ($25.8 million net operating cash outflow). Key factors impacting this improvement are: Customer receipts of $44.5 million, up from $5.4 million in the p ....

United States , United Kingdom , Waals Gewest , Czech Republic , South Africa , United Arab Emirates , Bruxelles Capitale , Comunidad Autonoma De Cataluna , New Zealand , South Korea , Kyahn Williamson , Kevin Richardson , University Of Queensland , Australian Securities Exchange , Industrial Transformation Research Program , Chinese National Medical Products Administration , Danish Medicines Agency , Ge Healthcare , Telix Pharmaceuticals , Board Of Directors Telix Pharmaceuticals , Drug Administration , Australian Research Council , Oncidium Foundation , European Association Of Nuclear Medicine , Australian Therapeutic Goods Administration , Group Limited Grand Pharma ,